bristol myers squibb stock news - Search News

Bristol Myers Squibb Stock Rises

Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic drugs.

Why Did Bristol-Myers Squibb Co (BMY) Stock See 34.20% Surge in the Last 90 Days?

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at $52.

Seeking Alpha · 6d

Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite potential risks. Read more on BMY here.

2d

Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend

Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...

6don MSN

Bristol-Myers Squibb stock jumps on schizophrenia drug approval

Bristol-Myers Squibb shares rose in premarket trade on Friday after the U.S. Food and Drug Administration approved a ...

Investor's Business Daily on MSN15h

Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

2d

Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results